Optiflow™ Nasal High Flow in the Emergency Department

Reduced escalation of care


Start a conversation about evaluating
 Optiflow Nasal High Flow
Recognize, stabalize, and mobilize graph

What clinical evidence is there, specific to the ED?


Reducing escalation in ED



Bell. 20151

Higher proportion of patients had > 20% reduction in respiratory rate using NHF: 66.7% NHF vs. 38.5% conventional oxygen therapy (COT), p=0.005.





Showed in an ED randomized control trial that NHF was associated with a lower proportion of patients requiring escalation in ventilation therapy.


Nasal high flow can decrease the need for escalation and might decrease the need for intubation.

(Meta-analysis; nasal high flow compared with COT and NIV)

- Huang, et al. Emerg Med Int. 2019.

“Patients with HFNC were much more likely to recover from respiratory failure.”

(Compared with COT in patients with acute hypoxemic respiratory failure)

- Mace, et al. Am J Emerg Med. 2019.




Optiflow in the ED: clinical studies summary

Emergency department clinical studies graph



References



Enquire about Optiflow nasal high flow therapy
If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.

CAPTCHA